<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-44802-2S4</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Towards a HIV-1 cure; detection and elimination of the HIV-1 reservoir</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Combination antiretroviral therapy (cART) is very potent insuppressing HIV-1 replication, blocking transmission, and preventing the development of AIDS, but it is not curative. HIV-1 persistence in reservoirs is the major obstacle to an HIV-1 cure, as viral replication rapidly resumes after cART interruption. A major focus has been on the reactivation of the HIV-1 reservoir by latency reversal agents.However, this current approach has been of limited success, attributed to the lack of both basic knowledge of the reservoir and efficient therapeutic strategies for its eradication. Consequently, novel curative treatments should specifically eradicate HIV-1 infected cells. In this project Target2Cure we combine the virological and immunological expertise of the scientists and the industrial partners. Together with our unique clinical infrastructure and innovative tools/approaches, we will develop novel approaches to identify and eliminate the HIV-1 reservoir to achieve a cure of HIV-1.In Work package 1 (WP1) we will develop novel sensitive biomarkers to detect HIV-1 persistence at the molecular and cellular level. In Work package 2 (WP2) we will develop innovative strategies to target the HIV-1 reservoir for eradication using HIV-1 specifictargeting approaches. Moreover, we will modulate molecularpathways to induce anti-HIV-1 immunity and/or specifically eliminate HIV-1-infected cells. In Work package 3 (WP3) we will investigate the efficacy of the developed methods, in both the human ex vivomodel using unique patient material as well as the in vivo latency humanized mouse model. We will also develop a novel in vivo imaging approach to monitor the dynamics of HIV-1 reactivation and eradication of HIV-1 reservoirs. Our industrial partners are involved in every work package and not only provide innovative tools and unique knowledge but also ensure that the findings will be further developed clinically to achieve a functional cure for HIV-1.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2019-10-01" type="2"></activity-date>
  <activity-date iso-date="2023-05-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C62" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2019-10-01"></period-start>
   <period-end iso-date="2023-05-31"></period-end>
   <value currency="EUR" value-date="2019-10-01">100000</value>
  </budget>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2019-08-26"></transaction-date>
   <value currency="EUR" value-date="2019-08-26">19147</value>
   <description>
    <narrative xml:lang="EN">Cash; gereserveerd in 2018, toegekend in 2019 (referentienummer 23231)
Aanvankelijk was er &#x20AC;100.000 gereserveerd uit 2018 voor 2019. Nu is er op het ADD 2019 &#x20AC;80.853 opgebracht voor dit project, vandaar dit bedrag van &#x20AC;19.147 (100k - 80.853) ipv de oorspronkelijke &#x20AC;100.000 die gereserveerd stond.

Totaal toegekende subsidiebedrag van &#x20AC;100.000 Aidsfonds aan AMC blijft onveranderd.</narrative>
   </description>
   <provider-org provider-activity-id="NL-KVK-41207989-" ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2023-10-31"></transaction-date>
   <value currency="EUR" value-date="2023-10-31">20000</value>
   <description>
    <narrative xml:lang="EN">Na goedkeuring eindrapportage</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2022-10-31"></transaction-date>
   <value currency="EUR" value-date="2022-10-31">40000</value>
   <description>
    <narrative xml:lang="EN">Na goedkeuring tweede tussentijdse rapportage</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2019-08-26"></transaction-date>
   <value currency="EUR" value-date="2019-08-26">80853</value>
   <description>
    <narrative xml:lang="EN">Opbrengst AmsterdamDiner 2019 voor doel Onderzoek genezing</narrative>
   </description>
   <provider-org provider-activity-id="NL-KVK-412115640001-" ref="NL-KVK-412115640001">
    <narrative xml:lang="EN">AmsterdamDiner Foundation</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2019-10-23"></transaction-date>
   <value currency="EUR" value-date="2019-10-23">40000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-10-23"></transaction-date>
   <value currency="EUR" value-date="2019-10-23">40000</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-25801" type="1"></related-activity>
 </iati-activity>
</iati-activities>
